Abstract
ODYSSEY Outcomes trial has proven alirocumab efficiency in lowering LDL cholesterol (LDL-C) concentrations as well as in reduction of cardiovascular risk and all-cause mortality. Results of the yet unpublished trial and its future analyses promise an advance in therapy focused on reduction of LDL-C concentrations and represent another argument for the availability of PCSK9 inhibitors in clinical practice.